Chinese Artemisinin Supplier Overtakes Novartis’ Export
This article was originally published in PharmAsia News
According to the latest statistics from China's Chamber of Commerce of Medicines & Health Products Importers & Exporters (CCCMPHIE), total local export of Artemisinin products reached $40 million in the first three quarters of last year. Guilin Pharmaceutical, a subsidiary of Shanghai Fosun Pharmaceutical, ranked one, toppling incumbent supplier Beijing Novartis. However, Novartis still dominates the global market, with most of its product made in the U.S. and only 10 percent contributed by Beijing Novartis. The present competition and uneven product standards have caused pricing of domestic Artemisinin to plunge. The Ministry of Commerce and related organizations are formulating regulations on Artemisinin export to bring more structure to the industry. (Click here for more)
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.